After extensive research in the field of Neuroscience, Dr. Jones developed a natural brain-defense compound called Sophrosyne Brain. Dr. Jones is an Assistant Professor of Medicine and Neuroscientist (Mayo Clinic alumni).
Sophrosyne Brain is a harmonious blend of natural Nootropic ingredients scientifically studied for their benefits on memory and cognition. Sophrosyne’s ingredients are present at the same doses as those used in human clinical trials, which showed significant improvements in both cognition and memory. Scientific studies have also been conducted in a laboratory setting, and the results indicate that the ingredients are effective at helping to maintain a healthy brain function.
Other names: Ashwagandha, Winter Cherry, Indian Ginseng, Ayurvedic Ginseng
Withania somnifera helps maintain a healthy brain by re-energizing tired brain cells. Laboratory studies have shown that this medicinal plant promotes optimal brain function by regulating the levels of beta-amyloid peptides, which are proteins involved in pathways affecting memory (1). Withania somnifera was also shown to induce the healthy growth of axons and dendrites within the brain, and nurture the formation of new synapses to promote efficient cell-to-cell communication (2).
Curcumin is the principal curcuminoid of turmeric, and a naturally occurring phenol. An 18-month clinical trial at UCLA performed in 51-84 year olds showed that subjects who took 180mg of a bioavailable form of curcumin per day had significant improvements in both verbal and visual memory, and also showed significantly improved attention. Brain imaging studies of these subjects revealed a significant reduction of amyloid and tau proteins in brain regions involved in mood and memory. In contrast, subjects who received placebo for 18 months had no improvements in any domain (3). Curcumin has also been studied in laboratory models, and was shown to inhibit the aggregation of amyloid-beta peptides and promoted the break-down of amyloid-beta peptide aggregates. Curcumin was also shown to promote brain cell-survival in a dose-dependent manner (4).
Other names: Brahmi, Herb of Grace, Water Hyssop
Bacopa monnieri is a natural source of bacosides. At least four randomized, double-blind, placebo controlled human clinical trials have shown that Bacopa monnieri enhances aspects of cognition and memory, and decreases the rate of forgetting newly acquired information (5-8). The mechanisms of action include the modulation of reactive species and the promotion of optimal DNA health (9). Bacopa monnieri was also shown to inhibit plasma AChE activity (7). AChE breaks down acetylcholine and other choline esters that function as our neurotransmitters, and thus Bacopa monnieri enhances memory and cognition by preventing the breakdown of such neurotransmitters.
Other names: Lion’s Mane*, Old Man’s Beard, Bearded Tooth, Pom Pom Mushroom
The artwork of Sophrosyne’s packaging is dedicated to this beautiful hair-like mushroom, commonly known as Lion’s Mane. Lion’s Mane, or Hericeum erinaceus, has been shown to stimulate Nerve Growth Factor (NGF) synthesis in the hippocampus, which is the “memory center” of the brain (10). Neurotrophic factors such as NGF promote brain-cell survival and stimulate neurite outgrowth within both the central nervous system and peripheral nervous system, and are essential to maintain and organize neurons functionally. In a 16-week double-blind, parallel, placebo-controlled human clinical trial, high doses of Hericeum erinaceus were found to increase cognitive function in 50- to 80-year old men and women who had previously shown some cognition problems (11). By working in harmony with Sophrosyne’s other Nootropics, Hericium erinaceus will symbiotically act to enhance human cognition, and serves as the ignition to our memory-fuel formula.
*No lion’s were harmed in the making of Sophrosyne.
- Sehgal N., Withania Somnifera Reverses Alzheimer’s Disease Pathology by Enhancing Low-Density Lipoprotein receptor-related protein in liver. PNAS. Volume 109, Number 9, February 2012. Pages 3510-3515.
- Kuboyama T., Neuritic Regeneration and Synaptic Reconstruction Induced by Withanolide A. British Journal of Pharmacology. Volume 144. February 2005. Pages 961-971.
- Small GW., et al., Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. The American Journal of Geriatric Psychiatry. Volume 26, Issue 3, March 2018. Pages 266-277.
- Yang F., et al., Curcumin Inhibits Formation of Amyloid Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo. The Journal of Biological Chemistry, Volume 280, Number 7, Issue of February 18, 2005. Pages 5892-5901.
- Calabrese C., Effects of a Standardized Bacopa Monnieri Extract on Cognitive Performance, Anxiety, and Depression in the Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Alternative and Complimentary Medicine. Volume 14, Number 6, 2008. Pages 707-713.
- Morgan A., Does Bacopa monnieri Improve Memory Performance in Older Persons? Results of a Randomized, Placebo-Controlled, Double-Blind Trial. The Journal of Alternative and Complimentary Medicine. Volume 16, Number 7, 2010. Pages 753-759.
- Peth-Nui, T., Effects of 12-Week Bacope Monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers. Evidence-Based Complementary and Alternative Medicine. Volume 2012. November 2012.
- Roodenrys, S., Chronic Effects of Brahmi (Bacopa Monnieri) on Human Memory. Neuropsychopharmacology. Volume 27, Number 2. 2002.
- Russo, A., Nitric Oxide-Related Toxicity in Cultured Astrocytes: Effect of Bacopa Monnieri. Life Sciences. Volume 73, 2003. Pages 1517-1526.
- (10)Mori, K., Nerve Growth Factor-Inducing Activity of Hericium Erinaceus in 1321N1 Human Astrocyte Cells. Biological and Pharmaceutical Bulletin. Volume 31, Issue 9. 2008. Pages 1727-1732.
- (11)Mori, K., Improving Effects of the Mushroom Yamabuskitake (Hericium Erinaceus) on Mild Cognitive Impairment: A Double-Blind Placebo-Controlled Clinical Trial. Volume 23, Issue 3. 2009. Pages 367-372.